person · Reporting owner

SABATINO THOMAS J JR

Disclosed activity across 6 companies

Tapewire entity: 13239
SEC CIK: 0001124182

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
NEW RITE AID, LLCRAD · Entity 87704	Chief Legal Officer	June 05, 2023	June 12, 2023
TRACTOR SUPPLY CO /DE/TSCO · Entity 3294	Interim General Counsel	February 09, 2026	February 26, 2026
Teligent, Inc.TLGT · Entity 134764	Director	July 21, 2021	July 22, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

NEW RITE AID, LLC

Report date June 05, 2023 · Filed June 12, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
No Securities OwnedSEC Table I · non-derivative	Direct	0	Reported balance Holding disclosure · report date 2023-06-05 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 0

TRACTOR SUPPLY CO /DE/

Report date February 09, 2026 · Filed February 26, 2026

This filing explicitly reported no securities owned.

Teligent, Inc.

Report date July 21, 2021 · Filed July 22, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	150,000	Reported balance After 2021-07-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-07-21 · Grant · Acquired 150,000 · Balance 150,000 F1: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock F3: Each non-employee director of the Issuer is entitled to receive an annual grant of restricted stock units ("RSUs") with a value of $75,000 on the date of grant, such grants to be effective as of the date of the 2021 annual meeting of stockholders, and annually thereafter. The closing price of the Issuer's common stock on the date of grant was $0.50. F2: The shares underlying the derivative securities shall vest fully on the first anniversary of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock

F2: The shares underlying the derivative securities shall vest fully on the first anniversary of grant.

F3: Each non-employee director of the Issuer is entitled to receive an annual grant of restricted stock units ("RSUs") with a value of $75,000 on the date of grant, such grants to be effective as of the date of the 2021 annual meeting of stockholders, and annually thereafter. The closing price of the Issuer's common stock on the date of grant was $0.50.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AETNA INC /PA/

Report date November 28, 2018 · Filed November 28, 2018

Section 16 reporting ended · disclosed 2018-11-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-11-28 transaction · row 1 1 source row Row 1 · 2018-11-28 · Disposition to issuer · Disposed 11,152 · Balance 0 F1: Converted pursuant to the merger agreement (the "Merger Agreement") between CVS Health Corporation ("CVS Health") and Aetna Inc. ("Aetna") into $145 in cash and 0.8378 shares of CVS Health Common Stock for each share of Aetna Common Stock.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $114.46	Direct	Reported balance After 2018-11-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-11-28 · Disposition to issuer · Disposed 39,237 · Balance 0 F2: Represents Stock Appreciation Rights ("SARs") granted under the Aetna Inc. 2010 Stock Incentive Plan (the "Plan") on May 10, 2016, of which 66.7% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to (a) $145 plus (b) 0.8378 multiplied by the average of the volume weighted averages of the trading prices of CVS Health Common Stock on each of the five consecutive trading days ending on the trading day two trading days prior to the closing date, less (c) the exercise price (the "SAR Amount"). Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $114.46	Direct	Reported balance After 2018-11-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-11-28 · Disposition to issuer · Disposed 64,086 · Balance 0 F2: Represents Stock Appreciation Rights ("SARs") granted under the Aetna Inc. 2010 Stock Incentive Plan (the "Plan") on May 10, 2016, of which 66.7% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to (a) $145 plus (b) 0.8378 multiplied by the average of the volume weighted averages of the trading prices of CVS Health Common Stock on each of the five consecutive trading days ending on the trading day two trading days prior to the closing date, less (c) the exercise price (the "SAR Amount"). Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $125.27	Direct	Reported balance After 2018-11-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-11-28 · Disposition to issuer · Disposed 67,417 · Balance 0 F3: Represents SARs granted under the Plan on February 17, 2017, of which 33.3% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash equal to the SAR Amount. Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-11-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-11-28 · Disposition to issuer · Disposed 18,348 · Balance 0 F4: Represents Performance Stock Units ("PSUs") earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on May 10, 2016. These PSUs were converted to time-vesting CVS Health Restricted Stock Units ("RSUs") pursuant to the terms of the Merger Agreement.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-11-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-11-28 · Disposition to issuer · Disposed 17,474 · Balance 0 F4: Represents Performance Stock Units ("PSUs") earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on May 10, 2016. These PSUs were converted to time-vesting CVS Health Restricted Stock Units ("RSUs") pursuant to the terms of the Merger Agreement.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-11-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-11-28 · Disposition to issuer · Disposed 8,382 · Balance 0 F5: PSUs earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on February 17, 2017. These PSUs were converted to time-vesting CVS Health RSUs pursuant to the terms of the Merger Agreement.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-11-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-11-28 · Disposition to issuer · Disposed 19,715 · Balance 0 F6: RSUs granted under the Plan on March 2, 2018. These RSUs were converted to CVS Health RSUs pursuant to the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Converted pursuant to the merger agreement (the "Merger Agreement") between CVS Health Corporation ("CVS Health") and Aetna Inc. ("Aetna") into $145 in cash and 0.8378 shares of CVS Health Common Stock for each share of Aetna Common Stock.

F2: Represents Stock Appreciation Rights ("SARs") granted under the Aetna Inc. 2010 Stock Incentive Plan (the "Plan") on May 10, 2016, of which 66.7% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to (a) $145 plus (b) 0.8378 multiplied by the average of the volume weighted averages of the trading prices of CVS Health Common Stock on each of the five consecutive trading days ending on the trading day two trading days prior to the closing date, less (c) the exercise price (the "SAR Amount"). Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement.

F3: Represents SARs granted under the Plan on February 17, 2017, of which 33.3% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash equal to the SAR Amount. Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement.

F4: Represents Performance Stock Units ("PSUs") earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on May 10, 2016. These PSUs were converted to time-vesting CVS Health Restricted Stock Units ("RSUs") pursuant to the terms of the Merger Agreement.

F5: PSUs earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on February 17, 2017. These PSUs were converted to time-vesting CVS Health RSUs pursuant to the terms of the Merger Agreement.

F6: RSUs granted under the Plan on March 2, 2018. These RSUs were converted to CVS Health RSUs pursuant to the terms of the Merger Agreement.

Merck & Co., Inc.

Report date November 03, 2009 · Filed November 04, 2009

Section 16 reporting ended · disclosed 2009-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2009-11-03 transaction · row 1 1 source row Row 1 · 2009-11-03 · Disposition to issuer · Disposed 73,124 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc., ("Merger") upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.23 · Expires 2013-05-18	Direct	Reported balance After 2009-11-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2009-11-03 · Disposition to issuer · Disposed 190,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.37 · Expires 2014-04-14	Direct	Reported balance After 2009-11-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2009-11-03 · Disposition to issuer · Disposed 250,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.57 · Expires 2014-04-30	Direct	Reported balance After 2009-11-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2009-11-03 · Disposition to issuer · Disposed 240,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.70 · Expires 2015-04-24	Direct	Reported balance After 2009-11-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2009-11-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2015-04-30	Direct	Reported balance After 2009-11-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2009-11-03 · Disposition to issuer · Disposed 170,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.91 · Expires 2016-04-30	Direct	Reported balance After 2009-11-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2009-11-03 · Disposition to issuer · Disposed 177,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Phantom Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2009-11-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2009-11-03 · Disposition to issuer · Disposed 62,117.06 · Balance 0 F4: Each unit of phantom stock is the economic equivalent of one share of common stock. F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc., ("Merger") upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.

F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.

F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement.

F4: Each unit of phantom stock is the economic equivalent of one share of common stock.

F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.

TENNECO INC

Report date November 17, 2022 · Filed November 21, 2022

Section 16 reporting ended · disclosed 2022-11-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-11-17 transaction · row 1 1 source row Row 1 · 2022-11-17 · Disposition to issuer · Disposed 15,737 · Balance 0 F1: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub (the "Merger Agreement"), upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share (the "Merger Consideration") in cash.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-11-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-11-17 · Disposition to issuer · Disposed 100,802 · Balance 0 F2: Reflects disposition of share-settled restricted stock units granted to the Reporting Person pursuant to Rule 16b-3. Pursuant to the Merger Agreement, upon completion of the Merger, each outstanding share-settled restricted stock unit of the Issuer became fully vested and was converted into the right to receive in cash an amount equal to the Merger Consideration multiplied by the number of shares underlying the award (subject to any applicable tax withholding).
Cash-Settled Performance Share UnitsSEC Table II · derivative / convertible security	Direct	182,850	Reported balance After 2022-11-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-11-17 · Grant · Acquired 182,850 · Balance 182,850 F3: Pursuant to the Merger Agreement, upon completion of the Merger, the outstanding cash-settled performance share units became vested at target level.
Cash-Settled Performance Share UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-11-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-11-17 · Disposition to issuer · Disposed 182,850 · Balance 0 F4: Pursuant to the Merger Agreement, upon completion of the Merger, the outstanding cash-settled performance share units were cancelled in exchange for the right to receive an amount in cash equal to the Merger Consideration multiplied by the number of shares underlying the award (subject to any applicable tax withholding).

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub (the "Merger Agreement"), upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share (the "Merger Consideration") in cash.

F2: Reflects disposition of share-settled restricted stock units granted to the Reporting Person pursuant to Rule 16b-3. Pursuant to the Merger Agreement, upon completion of the Merger, each outstanding share-settled restricted stock unit of the Issuer became fully vested and was converted into the right to receive in cash an amount equal to the Merger Consideration multiplied by the number of shares underlying the award (subject to any applicable tax withholding).

F3: Pursuant to the Merger Agreement, upon completion of the Merger, the outstanding cash-settled performance share units became vested at target level.

F4: Pursuant to the Merger Agreement, upon completion of the Merger, the outstanding cash-settled performance share units were cancelled in exchange for the right to receive an amount in cash equal to the Merger Consideration multiplied by the number of shares underlying the award (subject to any applicable tax withholding).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 17, 2022 Filed Nov 21, 2022 17:04 UTC	TENNECO INC TEN · Entity 11746	Disposition to issuerCash-Settled Performance Share Units · Derivative	182,850	$20.00	$3,657,000.00	Disclosure SEC source: 0001209191-22-058199 · doc4.xml · derivative · entry 4 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President* 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 182,850 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, upon completion of the Merger, the outstanding cash-settled performance share units were cancelled in exchange for the right to receive an amount in cash equal to the Merger Consideration multiplied by the number of shares underlying the award (subject to any applicable tax withholding). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, upon completion of the Merger, the outstanding cash-settled performance share units were cancelled in exchange for the right to receive an amount in cash equal to the Merger Consideration multiplied by the number of shares underlying the award (subject to any applicable tax withholding). F4 · derivative.expiration_date: Pursuant to the Merger Agreement, upon completion of the Merger, the outstanding cash-settled performance share units were cancelled in exchange for the right to receive an amount in cash equal to the Merger Consideration multiplied by the number of shares underlying the award (subject to any applicable tax withholding). Read SEC document
November 17, 2022 Filed Nov 21, 2022 17:04 UTC	TENNECO INC TEN · Entity 11746	GrantCash-Settled Performance Share Units · Derivative	182,850	$0.00	$0.00	Disclosure SEC source: 0001209191-22-058199 · doc4.xml · derivative · entry 3 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President* 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,850 Underlying: Class A Common Stock · 182,850 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon completion of the Merger, the outstanding cash-settled performance share units became vested at target level. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, upon completion of the Merger, the outstanding cash-settled performance share units became vested at target level. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, upon completion of the Merger, the outstanding cash-settled performance share units became vested at target level. Read SEC document
November 17, 2022 Filed Nov 21, 2022 17:04 UTC	TENNECO INC TEN · Entity 11746	Disposition to issuerRestricted Stock Units · Derivative	100,802	$20.00	$2,016,040.00	Disclosure SEC source: 0001209191-22-058199 · doc4.xml · derivative · entry 2 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President* 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 100,802 shares Expires not disclosed F2 · derivative.exercise_price: Reflects disposition of share-settled restricted stock units granted to the Reporting Person pursuant to Rule 16b-3. Pursuant to the Merger Agreement, upon completion of the Merger, each outstanding share-settled restricted stock unit of the Issuer became fully vested and was converted into the right to receive in cash an amount equal to the Merger Consideration multiplied by the number of shares underlying the award (subject to any applicable tax withholding). F2 · derivative.exercise_date: Reflects disposition of share-settled restricted stock units granted to the Reporting Person pursuant to Rule 16b-3. Pursuant to the Merger Agreement, upon completion of the Merger, each outstanding share-settled restricted stock unit of the Issuer became fully vested and was converted into the right to receive in cash an amount equal to the Merger Consideration multiplied by the number of shares underlying the award (subject to any applicable tax withholding). F2 · derivative.expiration_date: Reflects disposition of share-settled restricted stock units granted to the Reporting Person pursuant to Rule 16b-3. Pursuant to the Merger Agreement, upon completion of the Merger, each outstanding share-settled restricted stock unit of the Issuer became fully vested and was converted into the right to receive in cash an amount equal to the Merger Consideration multiplied by the number of shares underlying the award (subject to any applicable tax withholding). Read SEC document
November 17, 2022 Filed Nov 21, 2022 17:04 UTC	TENNECO INC TEN · Entity 11746	Disposition to issuerClass A Common Stock	15,737	$20.00	$314,740.00	Disclosure SEC source: 0001209191-22-058199 · doc4.xml · nonDerivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President* 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub (the "Merger Agreement"), upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share (the "Merger Consideration") in cash. F1 · price: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub (the "Merger Agreement"), upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share (the "Merger Consideration") in cash. Read SEC document
February 15, 2022 Filed Feb 16, 2022 18:51 UTC	TENNECO INC TEN · Entity 11746	Exercise / conversionRestricted Stock Units · Derivative	21,097	$0.00	$0.00	Disclosure SEC source: 0001209191-22-010327 · doc4.xml · derivative · entry 3 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President* 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,194 Underlying: Class A Common Stock · 21,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Reflects vesting of restricted stock units granted to the Reporting Person pursuant to Rule 16b-3, one third of which vest on each of the first three anniversaries of the grant date. Each restricted stock unit converts into one share of Class A Common Stock. F3 · derivative.exercise_date: Reflects vesting of restricted stock units granted to the Reporting Person pursuant to Rule 16b-3, one third of which vest on each of the first three anniversaries of the grant date. Each restricted stock unit converts into one share of Class A Common Stock. F3 · derivative.expiration_date: Reflects vesting of restricted stock units granted to the Reporting Person pursuant to Rule 16b-3, one third of which vest on each of the first three anniversaries of the grant date. Each restricted stock unit converts into one share of Class A Common Stock. F4 · balance_after: After giving effect to the transaction reported in this Report, the Reporting Person holds an aggregate 100,802 restricted stock units and no cash-settled restricted stock units. Read SEC document
February 15, 2022 Filed Feb 16, 2022 18:51 UTC	TENNECO INC TEN · Entity 11746	Tax withholdingClass A Common Stock	5,360	$10.59	$56,762.40	Disclosure SEC source: 0001209191-22-010327 · doc4.xml · nonDerivative · entry 2 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President* 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,737 F2 · kind: Reflects disposition of shares to the Issuer in the form of share withholding to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document
February 15, 2022 Filed Feb 16, 2022 18:51 UTC	TENNECO INC TEN · Entity 11746	Exercise / conversionClass A Common Stock	21,097	$0.00	$0.00	Disclosure SEC source: 0001209191-22-010327 · doc4.xml · nonDerivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President* 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects stock acquired upon the vesting of restricted stock units granted to the Reporting Person pursuant to Rule 16b-3. Read SEC document
February 01, 2022 Filed Feb 3, 2022 19:33 UTC	TENNECO INC TEN · Entity 11746	GrantRestricted Stock Units · Derivative	58,608	$0.00	$0.00	Disclosure SEC source: 0001209191-22-007043 · doc4.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President* 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,608 Underlying: Class A Common Stock · 58,608 shares Expires not disclosed F1 · derivative.exercise_price: Reflects restricted stock units granted to the Reporting Person pursuant to Section 16b-3, one third of which vest on each of the first three anniversaries of the grant date. Each restricted stock unit represents the contingent right to receive one share of Class A Common Stock. F1 · derivative.exercise_date: Reflects restricted stock units granted to the Reporting Person pursuant to Section 16b-3, one third of which vest on each of the first three anniversaries of the grant date. Each restricted stock unit represents the contingent right to receive one share of Class A Common Stock. F1 · derivative.expiration_date: Reflects restricted stock units granted to the Reporting Person pursuant to Section 16b-3, one third of which vest on each of the first three anniversaries of the grant date. Each restricted stock unit represents the contingent right to receive one share of Class A Common Stock. F2 · balance_after: After giving effect to the transaction reported in this Report, the Reporting Person holds an aggregate 121,899 restricted stock units and no cash-settled restricted stock units. Read SEC document
July 21, 2021 Filed Jul 22, 2021 17:03 UTC	Teligent, Inc. TLGT · Entity 134764	GrantRestricted Stock Units · Derivative	150,000	$0.00	$0.00	Disclosure SEC source: 0001104659-21-094962 · tm2123025d1_4.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock F3 · price: Each non-employee director of the Issuer is entitled to receive an annual grant of restricted stock units ("RSUs") with a value of $75,000 on the date of grant, such grants to be effective as of the date of the 2021 annual meeting of stockholders, and annually thereafter. The closing price of the Issuer's common stock on the date of grant was $0.50. F2 · derivative.exercise_date: The shares underlying the derivative securities shall vest fully on the first anniversary of grant. F2 · derivative.expiration_date: The shares underlying the derivative securities shall vest fully on the first anniversary of grant. Read SEC document
February 15, 2021 Filed Feb 17, 2021 19:49 UTC	TENNECO INC TEN · Entity 11746	GrantRestricted Stock Units · Derivative	63,291	$0.00	$0.00	Disclosure SEC source: 0001209191-21-011539 · doc4.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President* 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,291 Underlying: Class A Common Stock · 63,291 shares Expires not disclosed F1 · derivative.exercise_price: Reflects restricted stock units granted to the Reporting Person pursuant to Section 16b-3, one third of which vest on each of the first three anniversaries of the grant date. Each restricted stock unit represents the contingent right to receive one share of Class A Common Stock. F1 · derivative.exercise_date: Reflects restricted stock units granted to the Reporting Person pursuant to Section 16b-3, one third of which vest on each of the first three anniversaries of the grant date. Each restricted stock unit represents the contingent right to receive one share of Class A Common Stock. F1 · derivative.expiration_date: Reflects restricted stock units granted to the Reporting Person pursuant to Section 16b-3, one third of which vest on each of the first three anniversaries of the grant date. Each restricted stock unit represents the contingent right to receive one share of Class A Common Stock. Read SEC document
January 04, 2021 Filed Jan 6, 2021 11:16 UTC	Teligent, Inc. TLGT · Entity 134764	GrantStock Option · Derivative	2,000	$0.00 Strike: $0.74	$0.00	Disclosure SEC source: 0000352998-21-000005 · primary_doc.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2031-01-04 F2 · price: These securities were granted as part of the Issuer's equity compensation to its non-employee directors. F1 · derivative.exercise_date: These securities shall vest fully 12 months from the date of grant. Read SEC document
January 02, 2020 Filed Jan 3, 2020 11:01 UTC	Teligent, Inc. TLGT · Entity 134764	GrantStock Option · Derivative	20,000	$0.00 Strike: $0.42	$0.00	Disclosure SEC source: 0001104659-20-000642 · tm201128d6_4.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-02 F2 · price: These securities were granted as part of the Issuer's equity compensation to its non-employee directors. F1 · derivative.exercise_date: These securities shall vest fully 12 months from the date of grant. Read SEC document
October 02, 2019 Filed Oct 4, 2019 17:58 UTC	Teligent, Inc. TLGT · Entity 134764	GrantStock Option · Derivative	9,943	$0.00 Strike: $0.88	$0.00	Disclosure SEC source: 0001144204-19-047419 · tv530699_form4.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,943 Underlying: Common Stock · 9,943 shares Expires 2029-10-02 F1 · security: These securities were issued pursuant to the terms of the Non-employee Directors Compensation Policy as compensation for services provided to the Board for the fourth quarter of 2019. Read SEC document
July 01, 2019 Filed Jul 3, 2019 11:46 UTC	Teligent, Inc. TLGT · Entity 134764	GrantStock Option · Derivative	13,462	$0.00 Strike: $0.65	$0.00	Disclosure SEC source: 0001144204-19-033723 · tv524758_form4.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,462 Underlying: Common Stock · 13,462 shares Expires 2029-07-01 F1 · security: These securities were issued pursuant to the terms of the Non-employee Directors Compensation Policy as compensation for services provided to the Board for the third quarter of 2019. Read SEC document
May 31, 2019 Filed Jun 3, 2019 13:49 UTC	Teligent, Inc. TLGT · Entity 134764	PurchaseCommon Stock	25,000	$0.66	$16,520.00	Disclosure SEC source: 0001144204-19-029389 · tv522956_4.xml · nonDerivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.6575 to $0.67, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document
May 13, 2019 Filed May 15, 2019 18:23 UTC	Teligent, Inc. TLGT · Entity 134764	GrantStock Option · Derivative	10,174	$0.00 Strike: $0.86	$0.00	Disclosure SEC source: 0001144204-19-026691 · tv521751_form4.xml · derivative · entry 2 SABATINO THOMAS J JR · CIK 0001124182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,174 Underlying: Common Stock · 10,174 shares Expires 2029-05-13 F2 · security: These securities were issued pursuant to the terms of the Non-employee Director Compensation Policy as compensation for services provided to the Board in the second quarter of 2019. Read SEC document
May 13, 2019 Filed May 15, 2019 18:23 UTC	Teligent, Inc. TLGT · Entity 134764	GrantStock Option · Derivative	10,174	$0.00 Strike: $0.86	$0.00	Disclosure SEC source: 0001144204-19-026691 · tv521751_form4.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,174 Underlying: Common Stock · 10,174 shares Expires 2029-05-13 F1 · security: These securities were issued pursuant to the terms of the Non-employee Director Compensation Policy as compensation for services provided to the Board in the first quarter of 2019. Read SEC document
January 02, 2019 Filed Jan 4, 2019 16:03 UTC	Teligent, Inc. TLGT · Entity 134764	GrantStock Option · Derivative	20,000	$0.00 Strike: $1.32	$0.00	Disclosure SEC source: 0001144204-19-000657 · tv510286_4.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-02 F2 · price: These securities were granted as part of the Issuer's equity compensation to its non-employee directors. F1 · derivative.exercise_date: These securities shall vest fully 12 months from the date of grant. Read SEC document
November 28, 2018 Filed Nov 28, 2018 16:24 UTC	AETNA INC /PA/ AET · Entity 107289	Disposition to issuerRestricted Stock Units · Derivative	19,715	Not disclosed	Not disclosed	Disclosure SEC source: 0001122304-18-000165 · edgar.xml · derivative · entry 8 SABATINO THOMAS J JR · CIK 0001124182 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,715 shares Expires not disclosed F6 · derivative.exercise_price: RSUs granted under the Plan on March 2, 2018. These RSUs were converted to CVS Health RSUs pursuant to the terms of the Merger Agreement. F6 · price: RSUs granted under the Plan on March 2, 2018. These RSUs were converted to CVS Health RSUs pursuant to the terms of the Merger Agreement. F6 · derivative.exercise_date: RSUs granted under the Plan on March 2, 2018. These RSUs were converted to CVS Health RSUs pursuant to the terms of the Merger Agreement. F6 · derivative.expiration_date: RSUs granted under the Plan on March 2, 2018. These RSUs were converted to CVS Health RSUs pursuant to the terms of the Merger Agreement. Read SEC document
November 28, 2018 Filed Nov 28, 2018 16:24 UTC	AETNA INC /PA/ AET · Entity 107289	Disposition to issuerPerformance Stock Units · Derivative	8,382	Not disclosed	Not disclosed	Disclosure SEC source: 0001122304-18-000165 · edgar.xml · derivative · entry 7 SABATINO THOMAS J JR · CIK 0001124182 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,382 shares Expires not disclosed F5 · derivative.exercise_price: PSUs earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on February 17, 2017. These PSUs were converted to time-vesting CVS Health RSUs pursuant to the terms of the Merger Agreement. F5 · price: PSUs earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on February 17, 2017. These PSUs were converted to time-vesting CVS Health RSUs pursuant to the terms of the Merger Agreement. F5 · derivative.exercise_date: PSUs earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on February 17, 2017. These PSUs were converted to time-vesting CVS Health RSUs pursuant to the terms of the Merger Agreement. F5 · derivative.expiration_date: PSUs earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on February 17, 2017. These PSUs were converted to time-vesting CVS Health RSUs pursuant to the terms of the Merger Agreement. Read SEC document
November 28, 2018 Filed Nov 28, 2018 16:24 UTC	AETNA INC /PA/ AET · Entity 107289	Disposition to issuerPerformance Stock Units · Derivative	17,474	Not disclosed	Not disclosed	Disclosure SEC source: 0001122304-18-000165 · edgar.xml · derivative · entry 6 SABATINO THOMAS J JR · CIK 0001124182 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,474 shares Expires not disclosed F4 · derivative.exercise_price: Represents Performance Stock Units ("PSUs") earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on May 10, 2016. These PSUs were converted to time-vesting CVS Health Restricted Stock Units ("RSUs") pursuant to the terms of the Merger Agreement. F4 · price: Represents Performance Stock Units ("PSUs") earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on May 10, 2016. These PSUs were converted to time-vesting CVS Health Restricted Stock Units ("RSUs") pursuant to the terms of the Merger Agreement. F4 · derivative.exercise_date: Represents Performance Stock Units ("PSUs") earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on May 10, 2016. These PSUs were converted to time-vesting CVS Health Restricted Stock Units ("RSUs") pursuant to the terms of the Merger Agreement. F4 · derivative.expiration_date: Represents Performance Stock Units ("PSUs") earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on May 10, 2016. These PSUs were converted to time-vesting CVS Health Restricted Stock Units ("RSUs") pursuant to the terms of the Merger Agreement. Read SEC document
November 28, 2018 Filed Nov 28, 2018 16:24 UTC	AETNA INC /PA/ AET · Entity 107289	Disposition to issuerPerformance Stock Units · Derivative	18,348	Not disclosed	Not disclosed	Disclosure SEC source: 0001122304-18-000165 · edgar.xml · derivative · entry 5 SABATINO THOMAS J JR · CIK 0001124182 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,348 shares Expires not disclosed F4 · derivative.exercise_price: Represents Performance Stock Units ("PSUs") earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on May 10, 2016. These PSUs were converted to time-vesting CVS Health Restricted Stock Units ("RSUs") pursuant to the terms of the Merger Agreement. F4 · price: Represents Performance Stock Units ("PSUs") earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on May 10, 2016. These PSUs were converted to time-vesting CVS Health Restricted Stock Units ("RSUs") pursuant to the terms of the Merger Agreement. F4 · derivative.exercise_date: Represents Performance Stock Units ("PSUs") earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on May 10, 2016. These PSUs were converted to time-vesting CVS Health Restricted Stock Units ("RSUs") pursuant to the terms of the Merger Agreement. F4 · derivative.expiration_date: Represents Performance Stock Units ("PSUs") earned at a specified level in conjunction with the change in control of Aetna and pursuant to the terms of the relevant PSU award agreement. The PSUs were originally granted under the Plan on May 10, 2016. These PSUs were converted to time-vesting CVS Health Restricted Stock Units ("RSUs") pursuant to the terms of the Merger Agreement. Read SEC document
November 28, 2018 Filed Nov 28, 2018 16:24 UTC	AETNA INC /PA/ AET · Entity 107289	Disposition to issuerStock Appreciation Rights · Derivative	67,417	Not disclosed Strike: $125.27	Not disclosed	Disclosure SEC source: 0001122304-18-000165 · edgar.xml · derivative · entry 4 SABATINO THOMAS J JR · CIK 0001124182 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,417 shares Expires not disclosed F3 · price: Represents SARs granted under the Plan on February 17, 2017, of which 33.3% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash equal to the SAR Amount. Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement. F3 · derivative.exercise_date: Represents SARs granted under the Plan on February 17, 2017, of which 33.3% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash equal to the SAR Amount. Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement. F3 · derivative.expiration_date: Represents SARs granted under the Plan on February 17, 2017, of which 33.3% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash equal to the SAR Amount. Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement. Read SEC document
November 28, 2018 Filed Nov 28, 2018 16:24 UTC	AETNA INC /PA/ AET · Entity 107289	Disposition to issuerStock Appreciation Rights · Derivative	64,086	Not disclosed Strike: $114.46	Not disclosed	Disclosure SEC source: 0001122304-18-000165 · edgar.xml · derivative · entry 3 SABATINO THOMAS J JR · CIK 0001124182 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,086 shares Expires not disclosed F2 · price: Represents Stock Appreciation Rights ("SARs") granted under the Aetna Inc. 2010 Stock Incentive Plan (the "Plan") on May 10, 2016, of which 66.7% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to (a) $145 plus (b) 0.8378 multiplied by the average of the volume weighted averages of the trading prices of CVS Health Common Stock on each of the five consecutive trading days ending on the trading day two trading days prior to the closing date, less (c) the exercise price (the "SAR Amount"). Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement. F2 · derivative.exercise_date: Represents Stock Appreciation Rights ("SARs") granted under the Aetna Inc. 2010 Stock Incentive Plan (the "Plan") on May 10, 2016, of which 66.7% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to (a) $145 plus (b) 0.8378 multiplied by the average of the volume weighted averages of the trading prices of CVS Health Common Stock on each of the five consecutive trading days ending on the trading day two trading days prior to the closing date, less (c) the exercise price (the "SAR Amount"). Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement. F2 · derivative.expiration_date: Represents Stock Appreciation Rights ("SARs") granted under the Aetna Inc. 2010 Stock Incentive Plan (the "Plan") on May 10, 2016, of which 66.7% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to (a) $145 plus (b) 0.8378 multiplied by the average of the volume weighted averages of the trading prices of CVS Health Common Stock on each of the five consecutive trading days ending on the trading day two trading days prior to the closing date, less (c) the exercise price (the "SAR Amount"). Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement. Read SEC document
November 28, 2018 Filed Nov 28, 2018 16:24 UTC	AETNA INC /PA/ AET · Entity 107289	Disposition to issuerStock Appreciation Rights · Derivative	39,237	Not disclosed Strike: $114.46	Not disclosed	Disclosure SEC source: 0001122304-18-000165 · edgar.xml · derivative · entry 2 SABATINO THOMAS J JR · CIK 0001124182 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,237 shares Expires not disclosed F2 · price: Represents Stock Appreciation Rights ("SARs") granted under the Aetna Inc. 2010 Stock Incentive Plan (the "Plan") on May 10, 2016, of which 66.7% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to (a) $145 plus (b) 0.8378 multiplied by the average of the volume weighted averages of the trading prices of CVS Health Common Stock on each of the five consecutive trading days ending on the trading day two trading days prior to the closing date, less (c) the exercise price (the "SAR Amount"). Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement. F2 · derivative.exercise_date: Represents Stock Appreciation Rights ("SARs") granted under the Aetna Inc. 2010 Stock Incentive Plan (the "Plan") on May 10, 2016, of which 66.7% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to (a) $145 plus (b) 0.8378 multiplied by the average of the volume weighted averages of the trading prices of CVS Health Common Stock on each of the five consecutive trading days ending on the trading day two trading days prior to the closing date, less (c) the exercise price (the "SAR Amount"). Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement. F2 · derivative.expiration_date: Represents Stock Appreciation Rights ("SARs") granted under the Aetna Inc. 2010 Stock Incentive Plan (the "Plan") on May 10, 2016, of which 66.7% had vested. Each vested SAR was canceled pursuant to the terms of the Merger Agreement in exchange for an amount in cash for each SAR equal to (a) $145 plus (b) 0.8378 multiplied by the average of the volume weighted averages of the trading prices of CVS Health Common Stock on each of the five consecutive trading days ending on the trading day two trading days prior to the closing date, less (c) the exercise price (the "SAR Amount"). Each unvested SAR was converted to a CVS Health SAR pursuant to the terms of the Merger Agreement. Read SEC document
November 28, 2018 Filed Nov 28, 2018 16:24 UTC	AETNA INC /PA/ AET · Entity 107289	Disposition to issuerCommon Stock	11,152	Not disclosed	Not disclosed	Disclosure SEC source: 0001122304-18-000165 · edgar.xml · nonDerivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Converted pursuant to the merger agreement (the "Merger Agreement") between CVS Health Corporation ("CVS Health") and Aetna Inc. ("Aetna") into $145 in cash and 0.8378 shares of CVS Health Common Stock for each share of Aetna Common Stock. Read SEC document
March 02, 2018 Filed Mar 6, 2018 16:25 UTC	AETNA INC /PA/ AET · Entity 107289	GrantRestricted Stock Units · Derivative	19,715	$0.00	$0.00	Disclosure SEC source: 0001122304-18-000037 · edgar.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,715 Underlying: Common Stock · 19,715 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a right to receive one share of Aetna Inc. Common Stock net of taxes. F2 · derivative.exercise_date: RSUs granted under the Plan vest in three annual installments beginning December 2, 2018. F2 · derivative.expiration_date: RSUs granted under the Plan vest in three annual installments beginning December 2, 2018. Read SEC document
January 02, 2018 Filed Jan 4, 2018 16:20 UTC	Teligent, Inc. TLGT · Entity 134764	GrantStock Option · Derivative	20,000	$0.00 Strike: $3.85	$0.00	Disclosure SEC source: 0001144204-18-000825 · tv482607_form4.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-01-02 F2 · price: These securities were granted as part of the Issuer's equity compensation to its non-employee directors. F1 · derivative.exercise_date: These securities shall vest fully 12 months from the date of grant. Read SEC document
December 27, 2017 Filed Dec 29, 2017 16:04 UTC	AETNA INC /PA/ AET · Entity 107289	Exercise / conversionRestricted Stock Units · Derivative	21,842	$0.00	$0.00	Disclosure SEC source: 0001122304-17-000144 · edgar.xml · derivative · entry 3 SABATINO THOMAS J JR · CIK 0001124182 · Exec. VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,842 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a right to receive one share of Aetna Inc. Common Stock net of taxes. F3 · derivative.exercise_date: RSUs granted under the Plan. F3 · derivative.expiration_date: RSUs granted under the Plan. Read SEC document
December 27, 2017 Filed Dec 29, 2017 16:04 UTC	AETNA INC /PA/ AET · Entity 107289	Tax withholdingCommon Stock	10,690	$180.85	$1,933,286.50	Disclosure SEC source: 0001122304-17-000144 · edgar.xml · nonDerivative · entry 2 SABATINO THOMAS J JR · CIK 0001124182 · Exec. VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,152 Read SEC document
December 27, 2017 Filed Dec 29, 2017 16:04 UTC	AETNA INC /PA/ AET · Entity 107289	Exercise / conversionCommon Stock	21,842	Not disclosed	Not disclosed	Disclosure SEC source: 0001122304-17-000144 · edgar.xml · nonDerivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Exec. VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of previously reported Restricted Stock Units (RSUs) granted under the 2010 Stock Incentive Plan (the " Plan"). F2 · price: Each Restricted Stock Unit represents a right to receive one share of Aetna Inc. Common Stock net of taxes. Read SEC document
September 15, 2017 Filed Sep 19, 2017 16:48 UTC	Teligent, Inc. TLGT · Entity 134764	GrantStock Option · Derivative	20,000	$0.00 Strike: $7.19	$0.00	Disclosure SEC source: 0001144204-17-048687 · v475414_4.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-09-15 F2 · price: These securities were granted as part of the Issuer's equity compensation to its non-employee directors. F1 · derivative.exercise_date: These securities shall vest fully 12 months from the date of grant. Read SEC document
February 17, 2017 Filed Feb 22, 2017 19:20 UTC	AETNA INC /PA/ AET · Entity 107289	GrantStock Appreciation Rights · Derivative	67,417	$0.00 Strike: $125.27	$0.00	Disclosure SEC source: 0000950103-17-001631 · dp73206_4-sabatino.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,417 Underlying: Common Stock · 67,417 shares Expires 2027-02-17 F1 · derivative.exercise_date: Stock Appreciation Rights granted under the Aetna Inc. 2010 Stock Incentive Plan, exercisable in three annual installments beginning February 17, 2018. Read SEC document
November 03, 2009 Filed Nov 4, 2009 22:59 UTC	Merck & Co., Inc. SGP · Entity 2807	Disposition to issuerPhantom Stock Unit · Derivative	62,117.06	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 8 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 62,117.06 shares Expires not disclosed F4 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F5 · price: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. F5 · derivative.exercise_date: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. F5 · derivative.expiration_date: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. Read SEC document
November 03, 2009 Filed Nov 4, 2009 22:59 UTC	Merck & Co., Inc. SGP · Entity 2807	Disposition to issuerOption (right to buy) · Derivative	177,000	Not disclosed Strike: $22.91	Not disclosed	Disclosure SEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 7 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 177,000 shares Expires 2016-04-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document
November 03, 2009 Filed Nov 4, 2009 22:59 UTC	Merck & Co., Inc. SGP · Entity 2807	Disposition to issuerOption (right to buy) · Derivative	170,000	Not disclosed Strike: $18.85	Not disclosed	Disclosure SEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 6 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 170,000 shares Expires 2015-04-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document
November 03, 2009 Filed Nov 4, 2009 22:59 UTC	Merck & Co., Inc. SGP · Entity 2807	Disposition to issuerOption (right to buy) · Derivative	200,000	Not disclosed Strike: $20.70	Not disclosed	Disclosure SEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 5 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 200,000 shares Expires 2015-04-24 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document
November 03, 2009 Filed Nov 4, 2009 22:59 UTC	Merck & Co., Inc. SGP · Entity 2807	Disposition to issuerOption (right to buy) · Derivative	240,000	Not disclosed Strike: $31.57	Not disclosed	Disclosure SEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 4 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 240,000 shares Expires 2014-04-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document
November 03, 2009 Filed Nov 4, 2009 22:59 UTC	Merck & Co., Inc. SGP · Entity 2807	Disposition to issuerOption (right to buy) · Derivative	250,000	Not disclosed Strike: $17.37	Not disclosed	Disclosure SEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 3 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 250,000 shares Expires 2014-04-14 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document
November 03, 2009 Filed Nov 4, 2009 22:59 UTC	Merck & Co., Inc. SGP · Entity 2807	Disposition to issuerOption (right to buy) · Derivative	190,000	Not disclosed Strike: $19.23	Not disclosed	Disclosure SEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 2 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 190,000 shares Expires 2013-05-18 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document
November 03, 2009 Filed Nov 4, 2009 22:59 UTC	Merck & Co., Inc. SGP · Entity 2807	Disposition to issuerCommon Shares	73,124	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-09-051077 · c91856_4x1.xml · nonDerivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc., ("Merger") upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Read SEC document
May 01, 2009 Filed May 5, 2009 18:11 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantOption (right to buy) · Derivative	177,000	Not disclosed Strike: $22.91	Not disclosed	Disclosure SEC source: 0000310158-09-000054 · sab732.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,000 Underlying: Common Shares · 177,000 shares Expires 2016-04-30 F2 · price: Not Applicable. F1 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2006 Stock Incentive Plan and exercisable in one-third increments on May 1 of 2010, 2011 and 2012. The vesting of 35,400 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the 2009 year. Read SEC document
April 01, 2009 Filed Apr 3, 2009 18:49 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionDeferred Stock Unit Award · Derivative	30,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000310158-09-000028 · sab722.xml · derivative · entry 3 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document
April 01, 2009 Filed Apr 3, 2009 18:49 UTC	Merck & Co., Inc. SGP · Entity 2807	Tax withholdingCommon Shares	13,905	$23.70	$329,548.50	Disclosure SEC source: 0000310158-09-000028 · sab722.xml · nonDerivative · entry 2 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,124 Read SEC document
April 01, 2009 Filed Apr 3, 2009 18:49 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionCommon Shares	30,000	$0.00	$0.00	Disclosure SEC source: 0000310158-09-000028 · sab722.xml · nonDerivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document
February 27, 2009 Filed Mar 3, 2009 22:13 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantPhantom Stock Unit · Derivative	61,753	$0.00	$0.00	Disclosure SEC source: 0000310158-09-000011 · sab710.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,753 Underlying: Common Shares · 61,753 shares Expires not disclosed F1 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. The units of phantom stock will be held in the Issuer's Phantom Stock Fund under the Issuer's non-qualified deferred compensation plan, and will become payable, in cash, following the reporting person's termination of service. F1 · derivative.exercise_date: Each unit of phantom stock is the economic equivalent of one share of common stock. The units of phantom stock will be held in the Issuer's Phantom Stock Fund under the Issuer's non-qualified deferred compensation plan, and will become payable, in cash, following the reporting person's termination of service. F1 · derivative.expiration_date: Each unit of phantom stock is the economic equivalent of one share of common stock. The units of phantom stock will be held in the Issuer's Phantom Stock Fund under the Issuer's non-qualified deferred compensation plan, and will become payable, in cash, following the reporting person's termination of service. Read SEC document
May 01, 2008 Filed May 5, 2008 21:06 UTC	Merck & Co., Inc. SGP · Entity 2807	GrantOption (right to buy) · Derivative	170,000	Not disclosed Strike: $18.85	Not disclosed	Disclosure SEC source: 0000310158-08-000042 · sab667.xml · derivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Shares · 170,000 shares Expires 2015-04-30 F2 · price: Not Applicable. F1 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2006 Stock Incentive Plan and exercisable in one-third increments on May 1 of 2009, 2010 and 2011. The vesting of 34,000 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the 2008 year. Read SEC document
April 25, 2008 Filed Apr 29, 2008 20:05 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionDeferred Stock Unit Award · Derivative	35,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000310158-08-000022 · sab655.xml · derivative · entry 3 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document
April 25, 2008 Filed Apr 29, 2008 20:05 UTC	Merck & Co., Inc. SGP · Entity 2807	Tax withholdingCommon Shares	15,526	$18.64	$289,404.64	Disclosure SEC source: 0000310158-08-000022 · sab655.xml · nonDerivative · entry 2 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,029 Read SEC document
April 25, 2008 Filed Apr 29, 2008 20:05 UTC	Merck & Co., Inc. SGP · Entity 2807	Exercise / conversionCommon Shares	35,000	$0.00	$0.00	Disclosure SEC source: 0000310158-08-000022 · sab655.xml · nonDerivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.